Skip to main content

Gadoversetamide Dosage

Applies to the following strengths: 0.5 mmol/mL

Usual Adult Dose for Magnetic Resonance Angiography

For use with magnetic resonance imaging (MRI) in patients with abnormal blood brain barrier or abnormal vascularity of the brain, spine and associated tissues and to provide contrast enhancement and facilitate visualization of lesions with abnormal vascularity in the liver in patients who are highly suspect for liver structural abnormalities on computed tomography:

Bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) and at a rate of 1 to 2 mL/sec delivered by manual or by power injection.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available



  • NEPHROGENIC SYSTEMIC FIBROSIS (NSF): Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use in such patients unless the diagnostic information is essential and not available with noncontrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle, and internal organs. Do not administer this drug to patients with chronic, severe kidney disease (GFR less than 30 mL/min/1.73m2) or acute kidney injury. Patients should be screened for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g., greater than 60 years, hypertension, or diabetes), estimate the GFR through laboratory testing. Do not exceed the recommended dose and allow a sufficient period of time for elimination of the drug from the body prior to readministration-administration.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.